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Biliary innate immunity is involved in the pathogenesis of cholangiopathies in patients with primary biliary cirrhosis (PBC)
and biliary atresia. Biliary epithelial cells possess an innate immune system consisting of the Toll-like receptor (TLR) family
and recognize pathogen-associated molecular patterns (PAMPs). Tolerance to bacterial PAMPs such as lipopolysaccharides is also
important to maintain homeostasis in the biliary tree, but tolerance to double-stranded RNA (dsRNA) is not found. In PBC, CD4-
positiveTh17cellscharacterizedbythesecretionofIL-17areimplicatedinthechronicinﬂammationofbileductsandthepresence
of Th17 cells around bile ducts is causally associated with the biliary innate immune responses to PAMPs. Moreover, a negative
regulator of intracellular TLR signaling, peroxisome proliferator-activated receptor-γ (PPARγ), is involved in the pathogenesis of
cholangitis.ImmunosuppressionusingPPARγ ligandsmayhelptoattenuatethebileductdamageinPBCpatients.Inbiliaryatresia
characterized by a progressive, inﬂammatory, and sclerosing cholangiopathy, dsRNA viruses are speculated to be an etiological
agent and to directly induce enhanced biliary apoptosis via the expression of tumor necrosis factor-related apoptosis-inducing
ligand (TRAIL). Moreover, the epithelial-mesenchymal transition (EMT) of biliary epithelial cells is also evoked by the biliary
innate immune response to dsRNA.
1.Introduction
Clariﬁcation of the molecular mechanisms of innate immu-
nity and signiﬁcance of innate immune responses to the
pathogenesis of immune-mediated diseases as well as to the
defense against infections has progressed steadily since the
cloning of Tolls in drosophila and Toll-like receptors (TLRs)
in mammals including humans [1, 2]. Innate immunity
was initially thought to be limited to immunocompetent
cells such as dendritic cells and macrophages, but epithe-
lial cells also possess TLRs and proper innate immune
systems. Liver and extrahepatic bile ducts consisting of
hepatocytes and biliary epithelial cells (BECs) are also
exposed to microorganisms and their components originat-
ing from the intestines via portal blood and duodenum.
In the gastrointestinal tract, TLRs expressed in intestinal
epithelial cells may be involved in innate immunity to
maintain mucosal homeostasis and also the development
of enterocolitis by producing inﬂammatory molecules [3].
Similar processes using TLRs may operate in the biliary tree.
Human bile is sterile under normal conditions, but bacterial
components such as lipopolysaccharide (LPS), lipoteichoic
acid, and bacterial DNA fragments, known as pathogen-
associated molecular patterns (PAMPs), are detectable in
normal and pathologic bile [4–7], and cultivable bacteria
are also detectable in bile of patients with inﬂammatory
biliary diseases [8–11], indicating that BECs are exposed
to bacterial components under physiological as well as
pathological conditions (Table 1). Although hepatocytes are
usually infected by the hepatitis virus, no microorganisms
showing BEC-speciﬁc tropism have been identiﬁed. The
participation of microorganisms, however, in the etiology or
pathogenesis of various cholangiopathies and biliary diseases
has been reported or speculated. In this paper, we describe
the biliary innate immune system, its association with the
pathogenesis of cholangiopathy and biliary diseases, and
ﬁnally a strategy for the attenuation of cholangiopathy,
particularly cholangitis, by the regulation of innate immune
responses.2 Mediators of Inﬂammation
Table 1: Bacteria and viruses possible etiological of biliary diseases.
Primary biliary cirrhosis
(i) Detection of microorganisms
(a) lipopolysaccharide (LPS)
(b) lipoteichoic acid
(c) Helicobacter
(d) β-retrovirus
(e) P. acnes
(ii) Molecular mimicry between human and microbial PDC-E2
(a) E. coli
(b) Mycobacterium
(c) Novosphingobium
(d) Lactobacillus
(e) Chlamydia
(iii) Biliary atresia
(a) Reovirus
(b) Rotavirus
(c) cytomegalovirus (CMV)
(d) adenovirus
(e) enterovirus
(f) Ebstein-Barr virus (EBV)
(iv) Primary sclerosing cholangitis
(a) Helicobacter
(b) α-hemolytic streptococcus
(v) Hepatolithiasis
(a) Escherichia coli (E. coli)
(b) Klebsiella
(c) Streptococcus
(d) Pseudomonas
(e) Bacteroides
(f) Clostridium
(g) Campylobacter
2.AssociationwithBiliaryInnateImmunityin
BiliaryDiseases
Infectious agents have been implicated in the etiology or
progression of cholangiopathies including cholangitis, bile
duct loss, and lithiasis as a trigger or aggravating factor.
Notably, several enterobacteria and viruses are speculated to
be primary or secondary factor for primary biliary cirrhosis
(PBC), primary sclerosing cholangitis, biliary atresia, hepa-
tolithiasis, and chronic cholecystitis [4, 5, 12–16]( Table 1).
2.1. Primary Biliary Cirrhosis (PBC). PBC patients have an
increased incidence of recurrent urinary tract infections
compared to patients with other chronic liver diseases [17–
19]. Recent ﬁndings also support an association between
vaginal or urinary tract infections and PBC [20]. Further-
more, endotoxin and lipoteichoic acids abnormally accumu-
late in or around the intrahepatic bile ducts [7, 16, 21]a n d
DNA of Propionibacterium acnes (P. acnes) was detected as
a major clone in the granulomas of PBC patients (Table 1)
[22]. Because these bacterial components, whether proteins
or nucleic acids, act as PAMPs, the presence of PAMPs
in bile or around bile ducts is known to induce a variety
of inﬂammatory reactions and speculated to underlie the
etiopathogenesis of the cholangiopathy in cases of PBC.
The major autoantigens against antimitochondrial anti-
bodies (AMAs) in PBC are members of the 2-oxo-acid
dehydrogenase complex (2-OADC), which includes the E2
subunit of the pyruvate dehydrogenase complex (PDC-E2)
[23]. An immune response to intrahepatic BECs through 2-
OADC-speciﬁc CD4+ helper T cells and CD8+ cytotoxic T
cells is thought to be the major mechanism responsible for
the immunological destruction of BECs in PBC and these T
cells show molecular mimicry between human and bacterial
PDC-E2 [24, 25]. Therefore, environmental factors such as
microorganisms and xenobiotics are speculated to disrupt
the self-tolerance to autoantigens as a speciﬁc intrahepatic
BEC malfunction, supporting the forementioned role of
PAMPs in the etiopathogenesis of PBC.
2.2. Biliary Atresia. Biliary atresia consists of a fetal type
aﬀecting 10–25% of patients and the more common perina-
tal type. The perinatal type is characterized by a progressive,
inﬂammatory, and sclerosing cholangiopathy. The presence
of several viruses including Reoviridae (type 3 reovirus and
type C rotavirus) (Table 1) in liver tissue or aﬀected bile duct
specimens obtained from patients with biliary atresia during
the Kasai procedure or a liver transplantation, has been
demonstrated [13, 26–31], though conﬂicting results have
been reported [13, 26, 28–30, 32]. Immunostaining for Mx
proteins, which mediate an early innate immune response
and are highly sensitive markers for type I interferon (IFN)
activity, revealed that hepatocytes and intrahepatic bile
ducts in biliary atresia are positive for Mx, suggesting the
presence of viruses in hepatocytes and biliary epithelial cells
of patients with biliary atresia [33]. Among these viruses,
Reoviridaehavingadouble-strandedRNA(dsRNA)genome,
in particular, are characterized by epithelial tropism, and
rotavirustypeAisthemostfrequentetiologicalagentincases
of acute infantile diarrhea in young children. Moreover, the
infection of newborn Balb/c-mice with Reoviridae including
type A rhesus rotavirus (RRV) and type 3 reovirus (Abney)
leads to a cholestasis and biliary obstruction resembling
human biliary atresia [34, 35]. Therefore, it is likely that
BECs are a target of these viruses which directly cause the
cholangiopathy in cases of biliary atresia.
2.3. Hepatolithiasis. Hepatolithiasis is not a rare disease in
East Asian countries including Japan and is characterized by
the formation of stones and histologically “chronic prolifer-
ative cholangitis”. Bacterial infections in the biliary tree and
cholestasis have been implicated as the major etiopathogenic
factor for lithogenesis in patients with calcium-bilirubinate
stones. Escherichia coli (E. coli) is the bacterium most
frequently isolated, followed by several species shown to
have β-glucuronidase (Table 1). Moreover, the presence of
Campylobacter species-speciﬁc DNA has been demonstrated
in bile samples and biliary mucosa specimens in cases of
hepatolithiasis, by PCR (Table 1)[ 9]. These bacteria in theMediators of Inﬂammation 3
biliary epithelium are speculated to inﬂuence the occurrence
and development of cholangitis and lithogenesis, though the
mechanism of such an eﬀect is still unclear.
3.BasicMechanismsofBiliary
InnateImmunity
BECs are immunologically potent cells. The BECs of
inﬂamed bile ducts actively participate in the inﬂammation
by secreting cytokines and expressing immune receptors.
In addition to immunocompetent cells, epithelial cells
includingBECsrecognizemicrobesandtheirconstituentsvia
asetofreceptors,referredtoaspattern-recognitionreceptors
(PRRs). TLRs are the major epithelial PRRs recognizing
PAMPs. Ten TLRs (TLR1 to TLR10) have been identiﬁed
in humans, with TLR4 known to mediate inﬂammatory
responsestoLPS.Inimmunocompetentcells,theresponseto
LPS is mediated by interaction with the TLR4 in conjunction
with TLR4 accessory proteins MD-2 and CD14, triggering
transduction of intracellular signals followed by the activa-
tion of TLR-associated adapter proteins, myeloid diﬀerentia-
tion factor 88 (MyD88), and IL-1 receptor-associated kinase
(IRAK)-1,leadingtotheactivationofnuclearfactor-κB(NF -
κB) and then to the synthesis of antibiotics and proinﬂam-
matory cytokines. In contrast to bacterial PAMPs, dsRNA
viruses such as Reoviridaes (reovirus and rotavirus) are
recognized by TLR3, IFN-inducible helicase retinoic acid-
induced protein I (RIG-I), and melanoma diﬀerentiation-
associated gene-5 (MDA-5). The stimulation of these recep-
torsbydsRNAtransducessignalstoactivatethetranscription
factor interferon regulatory factor 3 (IRF3) as well as NF-
κB. Human and murine BECs possess at least TLR1-TLR5,
related molecules (MD-2, MyD88, and IRAK-1), RIG-I,
and MDA-5 [4, 36–38]. Moreover, immunohistochemistry
has conﬁrmed that TLR1-TLR5, MyD88, and IRAK-1 are
distributed diﬀusely in the intrahepatic biliary tree of
normal human liver, irrespective of anatomical levels [38]
(Figure 1). In addition to the expression of these receptors,
the responsiveness of BECs to the corresponding PAMPs
is also found. For example, LPS binds to the surface of
cultured BECs and induces the production of TNF-α mRNA
in an NF-κB-dependent manner [4]. Moreover, stimulation
with polyinosinic-polycytidylic acid (poly(I:C), a synthetic
analog of viral dsRNA) induces the activation of NF-κBa n d
IRF3 and the production of IFN-β1a n dM x Aa sp o t e n t
antiviral responses [37]. Therefore, BECs possess functional
TLR signaling systems and participate in innate immunity.
4. Chemical MediatorsProducedby
aBiliaryInnateImmune Response
Innate immunity provides defense against bacterial and
viral infections. Therefore, as part of an innate immune
response, several antibiotics are produced. Cytokines and
chemokines are also produced in immunocompetent cells
and play an important role in subsequent acquired immu-
nity. Moreover, BECs have been shown to secrete poly-
mericimmunoglobulinA,severalantibioticsagainstbacteria
Figure 1:RepresentativeexpressionpatternofTLR4ininterlobular
bile ducts. Membranous (mainly lateral) in addition to weakly
cytoplasmic expression is found in Primary biliary cirrhosis.
Immunohistochemistry for TLR4.
(lactoferrin, lysozyme, and defensins) and viruses (IFN-β1
and MxA), cytokines, and chemokines on treatment with
PAMPs, thereby contributing to biliary mucosal defense and
subsequent acquired immunity [39–41].
4.1. Defensin. Defensins are antimicrobial peptides identi-
ﬁed as key elements in innate immunity. Structurally, they
are divided into α-a n dβ-defensins. The β-defensin family is
distributed in the epithelium of several organs, constituting
an important barrier at mucosal surfaces. So far, human
β-defensins (hBD-1 to -6) have been identiﬁed. hBD-1
is constitutively expressed in cultured BECs and diﬀusely
distributed in the cytoplasm of intrahepatic bile ducts
irrespective of anatomical levels [42]( Figure 2). Moreover,
because hBD-1 is constantly detectable in bile samples,
hBD-1 it is believed to play a role in the constitutive
antimicrobial defense of the hepatobiliary system [42]. This
m a yb ew h yb i l i a r yt r a c ti n f e c t i o n sa r er a r ea n db i l ei ss t e r i l e
under physiological conditions, though the biliary tree is
potentially exposed to enteric bacteria. In contrast, hBD-2
is not detected in BECs cultured without a stimulant, but
de novo expression is found in LPS- or E. coli-treated BECs.
In vivo, hBD-2 expression is restricted to the intrahepatic
large bile ducts and peribiliary glands, in particular, showing
cholangitis in extrahepatic biliary obstruction and hepa-
tolithiasis (Figure 2)[ 42]. Because in these diseased livers,
entericbacteriaaremostlycultivableinbile,theparticipation
of bacteria-related cholangitis is closely associated with
the hBD-2 expression in BECs. Therefore, hBD-1 plays a
constitutive role in biliary antimicrobial defense, while hBD-
2 expression is induced in response to local infections and
may play a role in additional antimicrobial defenses.
4.2. Interleukin 8. IL-8 is a major cytokine of neutrophils,
and functions not only as a chemoattractant of neutrophils,
basophiles, and some populations of T cells, but also
as an activator of neutrophils for releasing leukotrienes,
activated oxygen, and neutrophil defensins. Bacteria or their
products have been reported to induce the secretion of4 Mediators of Inﬂammation
(a) (b)
Figure 2:Immunohistochemicalstainingforhumanbetadefensin(hBD)-1(a)andhBD-2(b).(a)Normalliver.Septalbileductsarepositive
for hBD-1. (b) Extrahepatic biliary obstruction. Biliary epithelium of the intrahepatic large bile duct showing cholangitis strongly expresses
hBD-2.
IL-8 from intestinal or gingival epithelial cells, and such
cytokines and chemokines are speculated to be involved in
epithelial cell damage during bacterial or fungal infections.
Cultured human BECs express and release IL-8 in response
to bacterial PAMPs including LPS [43]. IL-8 expression
is found in proliferating bile ductules in various diseased
livers and closely associated with neutrophilic inﬁltration
[43]. Particularly cholangitis lenta deﬁned as bile ductular
proliferation, ductular cholestasis, and ductular epithelial
damage, is also accompanied by a prominent neutrophilic
inﬁltration [44]. Cholangitis lenta is usually encountered in
septic conditions, so circulating infectious reagents such as
bacterial toxins or products, cytokines, or chemokines are
speculated to be involved in its pathogenesis. In a state of
sepsis, particularly endotoxemia, BECs may secrete IL-8 and
attract neutrophils to reactive bile ductules. IL-8 produced
in bile ductular biliary epithelia is a potential target in the
prevention of liver and biliary damage in diseased livers such
as septic liver.
4.3. Fractalkine. Fractalkine (CX3CL1) is a chemokine with
both chemoattractant and cell-adhesive functions and plays
an important role in the migration of leukocytes to target
sites under physiological as well as pathological conditions.
Fractalkine is expressed in several epithelial cells under nor-
mal conditions and involved in the chemoattraction to the
epithelial layerand adhesion of mononuclear cellsexpressing
its receptor, CX3CR1. The fractalkine level elevated in serum
concurrent with increased expression of CX3CR1 in liver-
inﬁltrating mononuclear cells in patients with PBC [45],
suggesting fractalkine to be critical for the generation and
persistence of the portal lymphocytic inﬁltration in PBC.
In fact, fractalkine is detectable in BECs of small bile ducts
in normal and diseased livers, but it is increased in injured
bile ducts of PBC [45]. Moreover, many CX3CR1-positive
mononuclear cells inﬁltrate into portal tracts and most
biliary intraepithelial lymphocytes in injured bile ducts are
also positive for CX3CR1. Production of fractalkine in BECs
is responsible for the chemoattraction of CX3CR1-positive
lymphocytes into portal tracts and into biliary epithelia [45].
Recently, Shimoda et al. [46] demonstrated the signiﬁcance
of fractalkine and the precise mechanism of its produc-
tion using populations of multiple intrahepatic cell types,
including endothelial cells, liver sinusoidal endothelial cells,
and BECs, to directly study the interaction of fractalkine-
producing cells with liver-inﬁltrating mononuclear cells.
Endothelialcellsproducedlargeamountsoffractalkineupon
stimulation by PAMPs, though liver sinusoidal endothelial
cells produced no fractalkine. Moreover, BECs also produced
fractalkine; TLR3-stimulated BECs produced fractalkine
after direct contact with TLR4-stimulated autologous mono-
cytes. Innate immunity may lead to increased expression of
fractalkine in the liver and contribute to the development of
cholangiopathy in cases of PBC.
5. Tolerance
The luminal surface of the biliary tree is continually exposed
to PAMPs via bile and/or portal blood, but no inﬂammatory
response is elicited in BECs. This lack of response to PAMPs,
especially LPS, could be due to “endotoxin tolerance,”
an important mechanism of maintaining the homeostasis
of organs such as the intestines which have commensal
bacterial ﬂora and to avoid excessive tissue damage [47]. In
addition to intestinal epithelial cells, BECs possess similar
tolerance; treatment with LPS for 24 hours signiﬁcantly
induced tolerance to a subsequent exposure to LPS as
assessed by measuring levels of NF-κB activity and TNF-
α mRNA production in cultured BEC cells (Figure 3)[ 48].
Moreover, pretreatment with Pam3CSK4 (TLR1/2 ligand)
eﬀectively induced tolerance to subsequent stimulation with
LPS (TLR4 ligand) (Figure 3)[ 48]. This cross-tolerance has
been demonstrated in monocytes and intestinal epithelial
cells [47]. However, treatment with poly(I:C) (TLR3 ligand)
signiﬁcantly enhanced NF-κB activity in fresh cultured BECs
and pretreatment did not lead to tolerance to poly(I:C)
(Figure 3)[ 49]. Levels of production of MxA and TRAIL
were also preserved. Therefore, tolerance to a TLR3 ligand
(poly(I:C)) is not found in BECs.Mediators of Inﬂammation 5
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Figure 3: Induction of tolerance in cultured human biliary epithe-
lial cells (BECs). BECs are pretreated with lipopolysaccharide (LPS,
TLR4 ligand) or Pam3CSK4(Pam3, TLR1/2 ligand) for 24 hours
and subjected to another LPS challenge. Pretreatment with LPS and
Pam3CSK4 signiﬁcantly decreases NF-κB activity in response to a
subsequent LPS challenge. In contrast, the pretreatment with poly
(I:C) (TLR3 ligand) or LPS does not inhibit NF-κB’s activation in
response to a subsequent poly (I:C) challenge (∗<. 05).
In response to LPS, the structural complex formed by
myeloid diﬀerentiation factor 88 (MyD88), IL-1 receptor-
associated kinase (IRAK)-1, IRAK-4, and TNF receptor-
associated factor 6 (TRAF6) induces a series of phosphoryla-
tion events, leading to the activation of nuclear transcription
factors. IRAK-M plays a critical negative regulatory role in
the signaling between MyD88 and IRAK-1 [50]. In LPS-
tolerant cultured BECs, levels of the IRAK-M mRNA and
protein were increased, implying that the expression of
IRAK-M interferes with the association between IRAK-1
and MyD88 and is crucial to the LPS-induced tolerance of
endotoxin in BECs [48]. Moreover, Pam3CSK4 as well as
LPS induced IRAK-M expression in BECs [48], suggesting
that the tolerance caused by the upregulation of IRAK-M
expression is also associated with cross-tolerance to LPS
induced by Pam3CSK4. Immunohistochemically, IRAK-M
was constitutively expressed in the cytoplasm of BECs, irre-
spective of intrahepatic biliary levels (Figure 4). This ﬁnding
suggests that the expression of IRAK-M is associated with
hypo- or unresponsiveness to bacterial PAMPs in bile and/or
portalﬂow.Incontrast,althoughIRAK-MmRNAexpression
was upregulated by stimulation with dsRNA (TLR3 ligand),
no tolerance to the dsRNA was found in cultured BECs. This
is reasonable because the intracellular signaling of dsRNA-
related receptors is a MyD88-independent pathway, that
is, the dsRNA-related response is not aﬀected by IRAK-
M[ 51]. Moreover, the upregulation of IRAK-M expression
on treatment with poly(I:C) is speculated to cause dsRNA-
stimulated BECs to become tolerant to TLR2- and TLR3-
related PAMPs including LPS. However, BECs are speculated
to be in an entirely virus-free state and at the time of
infection of a dsRNA virus, an innate response to dsRNA
develops and continues in the presence of virus in the biliary
tree, suggesting that the infection likely causes progressive
destruction in the biliary epithelium without inducing
tolerance.
Figure 4: IRAK-M is constitutively expressed in the cytoplasm of
septal bile ducts in normal liver. Immunohistochemistry for IRAK-
M.
6.Cholangiopathy Associatedwith
BiliaryInnateImmunity
6.1. Cell Death. BECs lining the biliary tree are toler-
ant of non-pathogenic commensal bacterial PAMPs so as
to maintain the homeostasis of biliary innate immunity
under physiological conditions. Even though biliary innate
immunity is activated by pathological PAMPs and provides
‘danger signals’ to the biliary tree, more eﬀective negative
mechanisms occur to avoid tissue damage.
However, because innate immune tolerance of dsRNA
is lacking in BECs, cell and tissue damage is found in the
biliary innate immune response via TLR3 [49]. Stimulation
with poly(I:C) induced the activation of NF-κBa n dI R F - 3 ,
followed by the production of antiviral IFN-β1[ 37] and also
enhanced apoptosis via production of tumor necrosis factor-
related apoptosis-inducing ligand (TRAIL) [37]. Moreover,
in biliary atresia in which Reoviridae are speculated to be
an etiological agent, BECs lining extrahepatic bile ducts
diﬀusely and constantly expressed TLR3 and showed an
enhancement of TRAIL and single-stranded DNA (ssDNA)-
positive apoptosis aswellastheactivationofNF-κBan dIRF -
3 and increased expression of an antiviral product, MxA [33,
37, 38]. Therefore, BECs not only directly participate in the
antiviral innate immune response through the production
of antiviral eﬀectors to prevent viral replication by secreting
antibiotics in response to dsRNA, but also play a role in
the generation of apoptotic responses to infected cells. This
additional mechanism concerning cell death in biliary innate
immunity is directly associated with the pathogenesis of
cholangiopathies in biliary atresia.
6.2. Epithelial-Mesenchymal Transition (EMT). Fundamen-
tal to EMT is a loss of normal epithelial features such
as cell-to-cell adhesion molecules and the gain of a mes-
enchymal phenotype [52]. Recently, the EMT of BECs has
been speculated to be associated with periductal ﬁbrosis
and portal ﬁbrosis in several chronic hepatobiliary diseases
[53–56]. In biliary atresia, in particular, the mesenchymal
markers vimentin, and S100A4 (also known as ﬁbroblast-
speciﬁc protein 1), and an essential transcription factor for
EMT, Snail, are expressed but the biliary-type cytokeratin6 Mediators of Inﬂammation
CK19 and the common epithelial marker E-cadherin are
not, in BECs of extrahepatic bile ducts and peribiliary
glands. The occurrence of EMT in the BECs of these
anatomical biliary components is closely associated with
the pathogenesis of sclerosing cholangiopathy in biliary
atresia [56, 57]. As mentioned, although the biliary innate
immune response to dsRNA reduces the viability of cultured
human BECs via TRAIL-mediated apoptosis, the rate of
cell death is approximately 30% [37]. The cells that evade
apoptosis show a gradual loss of CK19 and E-cadherin, and
increased expression of S100A4 and Snail, demonstrating the
occurrence of biliary EMT. Because EMT confers resistance
to apoptotic eﬀects in fetal rat hepatocytes [58], biliary EMT
is thought to be a survival mechanism and associated with
an incomplete induction of apoptosis caused by the biliary
innate immune response.
TGF-β1 and basic ﬁbroblast growth factor (bFGF)
are the major inducers of EMT and TGF-β1p l a y sa n
important role in the initiation and progression of liver
ﬁbrosis [59, 60]. Moreover, because expression of the TGF-
β1 pseudoreceptor, bone morphogenic protein and activin
membrane-bound inhibitor (Bambi), is decreased by an
innate immune response and consequently, susceptibility to
TGF-β1 is increased, loss of Bambi and upregulation of
the TGF-β receptor are also speculated to be inducers of
EMT [61]. Cultured human BECs constantly express TGF-
β1, its receptor TGFβR1, and the bFGF receptor (FGFR1)
[54, 57]. However, because Bambi is also expressed in BECs,
the induction of EMT is likely inhibited by the eﬀect of
Bambi. Treatment with poly (I:C) gradually decreases and
increases the expression of Bambi and bFGF, respectively,
and stimulation with bFGF quickly induces a reduction in
the level of Bambi. Therefore, the biliary innate immune
response to dsRNA could increase susceptibility to TGF-β1,
andbothTGF-β andbFGFplayimportantrolesinthebiliary
EMT induced by a dsRNA-related innate immune response.
6.3. Chronic Inﬂammation. Recently, in addition to Th1 and
Th2 cells, a third type of pathogenic helper T cell, the Th17
cell, and its association with the chronic inﬂammation of
autoimmune diseases, has been noted [62]. Human Th17
cells are characterized by the production of interleukin (IL)-
17 (IL-17A and IL-17F) and diﬀerentiate from na¨ ıve T cells
(Th0). Th17 cells are part of the mucosal host defense
system and have a major role in protection against bacterial
infections. Moreover, with the discovery that Th17 cells are
also involved in the pathogenesis of chronic inﬂammatory
disorders including models of some autoimmune diseases,
there has been intense interest in the relative contributions
of Th17 and Th1/Th2 cells to the pathogenesis of these
diseases. In liver, IL-17-positive cells identiﬁed as Th17 cells
are mainly present at the interface of inﬂammed portal tracts
in cases of PBC and CVH-C, and also, in PBC, accumulated
around damaged interlobular bile ducts [63]. Th17 cells are
associated with interface hepatitis in chronic liver diseases.
Moreover, the Th17-related peribiliary cytokine milieu is
enhanced in PBC and implicated in the histogenesis of the
sustained cholangitis of PBC.
In human Th17 cells, IL-6 and IL-1β are required for
diﬀerentiation [64], while IL-23 is necessary for maintaining
or stabilizing cellular functions and survival, but not dif-
ferentiation [62]. Bacterial PAMPs including LPS cause the
production of Th17-inducible cytokines (IL-6 and IL-1β)
and a Th17-maintaining cytokine (IL-23) in cultured BECs
[63]. Moreover, BECs lining damaged bile ducts in PBC,
express IL-6, IL-1β, and IL-23 p19 [63]. The biliary innate
immune response to bacterial components involves the
production of Th17-inducible and -maintaining cytokines
in BECs and also the diﬀerentiation into Th17 cells of
periductal dendritic cells and macrophages. Biliary innate
immunity plays a role in the induction and maintenance of
Th17 cells in the periductal area in cases of PBC.
7. Modulation of Biliary InnateImmunityas
aTherapeuticStrategy
Therapeutic strategies have been proposed for the mod-
ulation of hepatic innate immunity, but rarely for biliary
innate immunity. Peroxisome proliferator-activated receptor
γ (PPARγ) is a nuclear receptor involved in regulating
adipocyte diﬀerentiation and also antiinﬂammatory activi-
ties [65]. The activation of PPARγ by its ligands is shown
to inhibit the expression of proinﬂammatory cytokines
such as TNF-α, the induction of which is mediated via
NF-κB[ 66]. In liver, PPARγ is constitutively expressed in
intrahepatic bile ducts, irrespective of the anatomical level
(Figure 5), and may relate to the maintenance of biliary
homeostasis and absence of inﬂammatory reactions by
attenuating inﬂammatory signals in BECs to PAMPs [67]. In
PBC liver, PPARγ expression is signiﬁcantly downregulated
in the aﬀected bile ducts (Figure 5), indicating an increased
susceptibility to PAMPs. IL-4 (Th2 cytokine) and IFN-γ
(Th1 cytokine) up and downregulate PPARγ expression,
respectively, in cultured human BECs. An unique cytokine
milieu is associated with the reduction in PPARγ expression
in the aﬀected bile ducts of PBC liver [67].
SeveralPPARγ ligandshavebeenidentiﬁed,includingthe
prostaglandin D metabolite 15-deoxy-Δ12,14-prostaglandin
J2 (15d-PGJ2) and thiazolidinedione derivatives. 15d-PGJ2
functions as an endogenous ligand for PPARγ and attenuates
theactivationofNF-κBbypreventingthephosphorylationof
its inhibitor protein (I-κB). In cultured human BECs, 15d-
PGJ2 treatment attenuates PAMP (LPS or peptidoglycan)-
induced NF-κB activation and also TNF-α production
(Figure 6). PPARγ ligands provide protection against biliary
inﬂammation in PBC, but 15d-PGJ2 inhibited NF-κB’s
activation independent of PPARγ [67, 68]. In fact, a PPARγ
antagonist (GW9662) partially blocked the inhibitory eﬀects
o f1 5 d - P G J 2o nN F - κB activity. Therefore, 15d-PGJ2 is
expected to be eﬀective in the antiinﬂammatory treatment of
bile ducts with reduced as well as preserved PPARγ expres-
sion in PBC. Because PPARγ is a key immunomodulatory
molecule, a reduction in its expression in the bile ducts of
PBC liver may be important to the immunopathogenesis
of chronic cholangitis. Therefore, immunosuppression using
PPARγ ligands may help to reduce bile duct damage in PBC.Mediators of Inﬂammation 7
(a) (b)
Figure 5: Immunohistochemistry for peroxisome proliferator-activated receptor γ (PPARγ). (a) Normal liver. PPARγ is expressed in the
cytoplasm of bile ducts (arrow). (b) Primary biliary cirrhosis (PBC). Damaged bile ducts (arrowhead) show reduced expression of PPARγ,
though evidently positive biliary cells (arrow) also remain.
0
1
2
3
4
Non Non Non
Non Non LPS LPS PGN PGN
PGJ2 PGJ2 PGJ2 Pretreatment
Stimulants
N
F
-
κ
B
a
c
t
i
v
a
t
i
o
n
∗
∗
Figure 6: Eﬀect of the peroxisome proliferator-activated receptor
γ (PPARγ) ligand, 15d-PGJ2, on lipopolysaccharide (LPS, TLR4
ligand)- and peptidoglycan (PGN, TLR2 ligand)-induced NF-κB
activation in cultured human biliary epithelial cells (BECs). BECs
are pretreated in the presence or absence of 15d-PGJ2 (20μM)
before stimulation with LPS or peptidoglycan. Pretreatment with
15d-PGJ2 signiﬁcantly prevents PAMP-induced NF-κB activation
(∗<. 05).
8. Conclusion
Biliary innate immunity consisting of an organ-speciﬁc sys-
tem is important for the mucosal immunity in intrahepatic
and extrahepatic bile ducts. Biliary innate immunity is
surely associated with the pathogenesis of biliary diseases
as well as the defense against microbial infections. The
molecular mechanisms involved have recently been clariﬁed.
Targeting of NF-κB is thought to be a potential therapeutic
strategyinvariouscells,butTLRsignaling-speciﬁcmolecules
are also likely to be suitable molecular targets. Further
translational research concerning the regulation of biliary
innate immunity is needed.
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